Catalog No.: PC-21248Not For Human Use, Lab Use Only.
Pomotrelvir (PBI-0451) is a potent competitive inhibitor of SARS-CoV-2 Mpro (Ki=2.7 nM) with high selectivity against human proteases, inhibits wild-type SARS-CoV-2 Mpro with IC50 of 24 nM.
Pomotrelvir (PBI-0451) is a potent competitive inhibitor of SARS-CoV-2 Mpro (Ki=2.7 nM) with high selectivity against human proteases, inhibits wild-type SARS-CoV-2 Mpro with IC50 of 24 nM.
Pomotrelvir (PBI-0451) inhibits P132H variant, which is commonly observed in Omicron isolates and has been shown to have no effect on nirmatrelvir inhibition.
Pomotrelvir (PBI-0451) shows broad-spectrum activity against Mpro enzymes from other pathogenic and common cold CoV strains with IC50 ranging from 61 to 379 nM.
Pomotrelvir (PBI-0451) exhibits high selectivity against host proteases.
Pomotrelvir inhibits SARS-CoV-2 with EC50 ofof 32 nM (by plaque assay) and 36 nM (by qRT-PCR) in the SARS CoV-2 assay in iPS-AT2 cells and 23 nM in the SARS-CoV-2 NLuc assay, respectively.
